Global Information
회사소개 | 문의 | 비교리스트

만성 두드러기 : 파이프라인 리뷰

Chronic Urticaria Or Hives - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213077
페이지 정보 영문 140 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


만성 두드러기 : 파이프라인 리뷰 Chronic Urticaria Or Hives - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 140 Pages

만성 두드러기는 융기한 다양한 크기의 적색 또는 백색의 가려움을 수반하는 부어오름(팽진)이 나타나거나 사라지는 증상을 가리킵니다. 대부분의 경우 두드러기는 1주일 이내에 치료되지만, 그 중에는 장기적으로 증상이 계속되는 사람들도 있습니다. 6주간 이상 지속되는 두드러기와 일단은 소실되지만 자주 재발하는 두드러기를 만성 두드러기라고 합니다.

세계 각국에서의 만성 두드러기(Chronic Urticaria Or Hives) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 각 임상 단계별 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

만성 두드러기 개요

치료제 개발

  • 파이프라인 제품 개요

만성 두드러기 : 기업에서 개발중인 치료제

만성 두드러기 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

만성 두드러기 : 기업에서 개발중인 제품

만성 두드러기 치료제 개발에 참여하고 있는 기업

  • AstraZeneca Plc
  • Biofrontera AG
  • ELORAC, Inc.
  • Faes Farma, SA
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • J Uriach Y Compania, S.A.
  • Mabtech Limited
  • Merck & Co., Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Panacea Biotec Limited

만성 두드러기 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

만성 두드러기 : 최근의 파이프라인 동향

만성 두드러기 : 휴지중인 프로젝트

만성 두드러기 : 개발이 중지된 제품

만성 두드러기 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.03

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Allakos Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by BiOraliX BV, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Eli Lilly and Co, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Gossamer Bio Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, H1 2020
  • Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, H1 2020
  • Chronic Urticaria Or Hives - Dormant Projects, H1 2020
  • Chronic Urticaria Or Hives - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 9, 6, 1 and 1 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Urticaria Or Hives - Overview
  • Chronic Urticaria Or Hives - Therapeutics Development
  • Chronic Urticaria Or Hives - Therapeutics Assessment
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
  • Chronic Urticaria Or Hives - Drug Profiles
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q